2006
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiology And Drug Safety 2006, 15: 213-220. PMID: 16456879, DOI: 10.1002/pds.1207.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsAlanine TransaminaseAnti-Inflammatory Agents, Non-SteroidalArchivesBenzophenonesBiomarkersBromobenzenesChemical and Drug Induced Liver InjuryHumansLiverPhenylacetatesPropionatesRandomized Controlled Trials as TopicUnited StatesUnited States Food and Drug AdministrationConceptsAcute liver failureNonsteroidal anti-inflammatory drugsSerious hepatotoxicityLiver failureRisk of ALFSystematic reviewDifferent nonsteroidal anti-inflammatory drugsCommon adverse eventsHepatic enzyme elevationFlu-like symptomsDrug-induced hepatotoxicityAnti-inflammatory drugsClinical trial dataSymptomatic hepatitisALT elevationElevated transaminasesAdverse eventsEnzyme elevationDrug withdrawalHepatocellular jaundiceRare caseMedWatch systemDrug AdministrationHepatotoxicityTrial data
2004
The hepatotoxicity of non‐steroidal anti‐inflammatory drugs
Rubenstein JH, Laine L. The hepatotoxicity of non‐steroidal anti‐inflammatory drugs. Alimentary Pharmacology & Therapeutics 2004, 20: 373-380. PMID: 15298630, DOI: 10.1111/j.1365-2036.2004.02092.x.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drug usersNon-steroidal anti-inflammatory drugsAnti-inflammatory drugsLiver injuryDrug usersParticular non-steroidal anti-inflammatory drugsComparative riskPopulation-based epidemiological studyRare complicationExcess riskRelevant hepatotoxicityInclusion criteriaMethodological qualityEpidemiological studiesPrecise riskPatient countsCumulative exposureInjuryHospitalizationDrugsRiskHepatotoxicityIncidenceCurrent useDeath